ARTICLE | Finance
Reasonable rally
Why biotech's rally should continue in 4Q16, but not at the pace of the prior quarter
October 3, 2016 7:00 AM UTC
It looks like biotech's rebound will continue through the end of the year, but not with enough gusto to match the third quarter, or to make up for losses in the first half.
After the first half beating, an undercurrent of M&A and a bumper crop of follow-on financings that rewarded buyers with after-market moves led the sector to beat out the broader markets in 3Q...